Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 17 June 2021. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that patient recruitment into the IPAX-1 Ph I/II study of TLX101 (4-L-[^{131}I] iodo-phenylalanine) in combination with external beam radiation therapy in recurrent glioblastoma multiforme (GBM), will be closed. Interim analysis of safety and preliminary efficacy is sufficiently encouraging to warrant study in front-line therapy, where radiation therapy is more extensively used. As such, the Company has decided to cease recruitment after dosing a tenth patient in this recurrent disease (second-line) treatment setting.

TLX101 is under evaluation for the treatment of recurrent glioblastoma multiforme (GBM) at five sites in Australia and Europe (IPAX-1 study details can be accessed here: NCT03849105). Recurrent GBM is a highly aggressive cancer that progresses rapidly, and for which there are few effective treatment options. TLX101 is a systemically administered molecularly-targeted radiation (MTR) investigational asset that targets L-type amino acid transporter 1 (LAT-1), which is typically over-expressed in GBM. TLX101 has been granted orphan drug designation in the US and Europe.

Telix Chief Medical Officer, Dr. Colin Hayward stated, "We are highly encouraged by the safety profile of this single arm dose-escalation study, where different dosing regimens have been combined with external radiation therapy. Whilst a small study of ten patients, promising overall survival and anti-tumour response observed from longitudinal imaging supports the decision to progress this candidate into an earlier line of therapy. A follow-on study is currently in planning to accelerate the development of TLX101 in this important therapy area with high unmet medical need."

Telix will release a complete set of safety and efficacy data upon completion of the study report.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix's lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,[1] and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).[2] Telix is also progressing marketing authorisation applications for Illuccix® in the European Union[3] and Canada.[4] None of Telix's products have received a marketing authorisation in any jurisdiction.

Telix Corporate Contact

Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
Managing Director and CEO
Email: chris.behrenbruch@telixpharma.com

Telix Corporate Communications

Dr. Stewart Holmstrom
Telix Pharmaceuticals Limited
Director of Corporate Communications
Email: stewart.holmstrom@telixpharma.com

[1] ASX disclosure 24/11/20.
[2] ASX disclosure 14/04/21.
[3] ASX disclosure 1/05/20.
[4] ASX disclosure 16/12/20.

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.